“Scientific talent is everywhere. Scientific resources are not. We want to change that,” said Dr. Heng Ji, Director of the Apodex Drug Research Computing Center. For Ji, the mission is deeply personal. Over the years, she has watched people very dear to her suffer from devastating diseases, including liver cancer, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). She has seen how illness can transform people's lives, taking away their independence, their ability to do things they once loved, and their plans for the future.
Many important medical needs remain underserved – not necessarily because promising scientific ideas are lacking, but because the resources required to investigate them are unavailable.
Ji believes AI can help change this imbalance by making sophisticated drug research capabilities accessible to a much broader scientific community. “I want world-class drug research computing to become a shared scientific resource – not a privilege,” she said.
Beyond prediction: better drug-development decisions
While much of the attention surrounding AI-driven drug discovery centers on designing new molecules, Apodex is also focused on another challenge: helping researchers make better decisions about drugs and development candidates that already exist. That includes identifying potential new therapeutic uses, investigating biological mechanisms, evaluating risks, and determining what evidence should be collected next.
Thousands of drugs and drug candidates have been developed, yet many never reach patients because of uncertain efficacy, safety concerns, formulation limitations, unsuccessful clinical trials, or incomplete understanding of their mechanisms. Which drugs should advance? Which might benefit a different patient population? When should researchers gather more evidence, change course, or stop? These decisions are especially consequential for rare and neglected diseases, where research resources are limited.
Putting evidence to work
Apodex aims to address these questions through AI-powered drug-development decision intelligence. The Apodex Drug Research Computing Center is built around a simple principle: advanced scientific infrastructure should be accessible to more of the research community.
It combines an integrated biomedical knowledge network, scientific literature, specialized computational tools, large-scale computing, and knowledge-equipped AI agents to support evidence-grounded investigation.
Rather than simply produce a plausible answer, the system is designed to explore mechanisms, examine supporting and contradictory evidence, and help researchers identify useful next steps. Scientists remain responsible for interpreting results and determining what deserves further testing.
The Centre is already applying this approach to clinical-trial forecasting, publishing predictions alongside concluded-trial examples so researchers can examine how forecasts compare with actual outcomes. As more trial outcomes become available, the record can be evaluated over time including where forecasts prove wrong.
The Centre offers research engagement in drug repurposing, reformulation, and drug–drug interaction analysis. These are distinct capabilities with different levels of availability and validation, and research findings should be evaluated on that basis.
Discovery requires verification
Scientific discovery requires more than generating a plausible hypothesis. It requires comparing possible explanations, inspecting contrary evidence, acknowledging uncertainty, and allowing real-world results to challenge an initial conclusion.
This emphasis on verification connects the Centre to Apodex’s broader ambition: to help humanity investigate questions whose answers are not yet known, while keeping accountable human judgment central.
Opening access, responsibly
For approved projects whose results are shared publicly, the Centre offers AI-powered drug research services without upfront research and computing fees within the agreed scope.
Projects requiring private results have fees agreed before work begins. The Centre aims to make published forecasts and research reports accessible under its applicable access terms, so that other researchers can examine the evidence, uncertainties, and limitations and assess whether the findings hold up.
These capabilities are intended to support physicians, academic laboratories, rare-disease researchers, and smaller biotechnology organisations that may otherwise lack the computing resources and multidisciplinary expertise needed for such investigations.
The Center’s open-science commitment will coexist with safeguards for privacy, intellectual property, scientific quality, and safety. What can be disclosed, shared, or reused will depend on applicable permissions and project agreements.
Making advanced scientific infrastructure more accessible is only the beginning; its value will depend on whether researchers use it to test useful ideas and make better decisions about medicines patients need.
Apodex invitse researchers and drug developers to bring forward difficult problems that deserve investigation-and that evidence can ultimately test. Scientific talent is everywhere. The resources to support it should be, too.
Learn more: https://drug.apodexlab.ai/
